Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel, Single-Dose Study to Assess the Pharmacokinetics and Safety of Levornidazole Disodium Phosphate for Injection in Subjects With Varying Degrees of Renal Impairment

NCT07033182 is registered in ClinicalTrials.gov with Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT07033182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07033182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel, Single-Dose Study to Assess the Pharmacokinetics and Safety of Levornidazole Disodium Phosphate for Injection in Subjects With Varying Degrees of Renal Impairment
Lead sponsor
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 30, 2023
Completion date
June 13, 2024
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections caused by anaerobic bacteria, renal impairment